Literature DB >> 31305880

Assessment of The Bethesda System for Reporting Thyroid Cytopathology.

Jennifer L Sauter1,2, Heidi Lehrke1, Xiaotun Zhang1, Osamah T Al Badri1, Rene Rodriguez-Gutierrez3,4,5,6, Danae A Delivanis3, Naykky Singh Ospina3,7, Diane Donegan3, Oksana Hamidi3,8, Nicole Iñiguez-Ariza3,9, Anu Sharma3, Nana Esi N Kittah3, Shrikant U Tamhane3, Maria D Hurtado Andrade3, Anupam Kotwal3, Sarah M Jenkins10, Grant Spears10, Michael Rivera1, Diana S Dean3, Michael R Henry1.   

Abstract

OBJECTIVES: Long-term follow-up is important for determining performance characteristics of thyroid fine-needle aspiration (FNA).
METHODS: Histologic or 3 or more years of clinical follow-up was used to calculate performance characteristics of thyroid FNA before and after implementation of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) classification was also investigated.
RESULTS: Follow-up was obtained for 1,277/1,134 and 1,616/1,393 aspirates/patients (median clinical follow-up, 9.9 and 4.4 years, pre- and post-TBSRTC, respectively). Nondiagnostic, suspicious for follicular neoplasm, and suspicious for malignancy (SFM) diagnoses decreased and benign diagnoses increased post-TBSRTC, while atypical rate remained less than 1%. Negative predictive value for benign nodules and positive predictive value (PPV) for SFM increased significantly. Eleven nodules were reclassified as NIFTP, slightly decreasing PPV/risk of malignancy (ROM).
CONCLUSIONS: Appropriate ROM for thyroid FNA can be achieved through application of TBSRTC terminology with minimal use of atypical category. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Atypia of undetermined significance/follicular lesion of undetermined significance; Bethesda; Cytopathology; FNA; Fine-needle aspiration; Follicular neoplasm/suspicious for follicular neoplasm; Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); Papillary thyroid carcinoma; Risk of malignancy; Thyroid

Mesh:

Year:  2019        PMID: 31305880     DOI: 10.1093/ajcp/aqz076

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

Review 1.  Thyroid Nodule Evaluation and Management in Older Adults: A Review of Practical Considerations for Clinical Endocrinologists.

Authors:  Naykky Singh Ospina; Maria Papaleontiou
Journal:  Endocr Pract       Date:  2021-02-12       Impact factor: 3.443

2.  The Impact of Regional Variation in Clinical Practice on Thyroid Cancer Diagnosis: A National Population-Based Study.

Authors:  Brigitte Decallonne; Annick Van den Bruel; Gilles Macq; Nathalie Elaut; Harlinde De Schutter
Journal:  Eur Thyroid J       Date:  2019-11-21

3.  Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy.

Authors:  Chunfang Hu; Weiwei Jing; Qing Chang; Zhihui Zhang; Zhenrong Liu; Jian Cao; Linlin Zhao; Yue Sun; Cong Wang; Huan Zhao; Ting Xiao; Huiqin Guo
Journal:  Mol Oncol       Date:  2022-03-12       Impact factor: 7.449

Review 4.  [The value of molecular testing of thyroid aspirates].

Authors:  O Chijioke
Journal:  Pathologe       Date:  2022-01-10       Impact factor: 1.011

5.  Diagnostic performance of next-generation sequencing and genetic profiling in thyroid nodules from a single center in China.

Authors:  Min Ren; Qianlan Yao; Longlong Bao; Zhiting Wang; Ran Wei; Qianming Bai; Bo Ping; Cai Chang; Yu Wang; Xiaoyan Zhou; Xiaoli Zhu
Journal:  Eur Thyroid J       Date:  2022-05-27

6.  Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules.

Authors:  Max A Schumm; Dalena T Nguyen; Jiyoon Kim; Chi-Hong Tseng; Amy Y Chow; Na Shen; Masha J Livhits
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.